Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes

Michael Lincoff, A.; Brown‐Frandsen, Kirstine; M. Colhoun, Helen; Deanfield, John; S. Emerson, Scott; Esbjerg, Sille; Hardt‐Lindberg, Søren; Kees Hovingh, G.; E. Kahn, Steven; F. Kushner, Robert; Lingvay, Ildiko; Kalaycı Oral, Tuğçe; Mide Michelsen, Marie; Plutzky, Jorge; W. Tornøe, Christoffer; H. Ryan, Donna

doi:10.1056/nejmoa2307563

Public

Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes

Published in New England Journal of Medicine • Nov 11, 2023

Authors:

A. Michael Lincoff

Kirstine Brown‐Frandsen

Helen M. Colhoun

Abstract

BACKGROUND: Semaglutide, a glucagon-like peptide-1 receptor agonist, has been shown to reduce the risk of adverse cardiovascular events in patients with diabetes. Whether semaglutide can reduce cardiovascular risk associated with overweight and obesity in the absence of diabetes is unknown. METHODS:...

Subject

Semaglutide

Medicine

Placebo

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!